We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Central Serous Chorioretinopathy: Etiology, Course and Prognosis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01378130
First Posted: June 22, 2011
Last Update Posted: April 26, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Stefan Sacu, Medical University of Vienna
  Purpose
Pathogenesis of central serous chorioretinopathy is not entirely understood yet, therefore further investigations are needed. During this study patients with an acute episode of central serous chorioretinopathy are observed with established ophthalmologic methods (multimodal imagine) every 6 weeks until subretinal fluid is reabsorbed to gain further insides in etiology, course and prognosis of this disease.

Condition
Central Serous Chorioretinopathy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Central Serous Chorioretinopathy: An Observational Study About Etiology, Course and Prognosis

Resource links provided by NLM:


Further study details as provided by Stefan Sacu, Medical University of Vienna:

Primary Outcome Measures:
  • Clinical Outcome [ Time Frame: 2 years ]
    OCT, Visus


Secondary Outcome Measures:
  • Subclinical Data [ Time Frame: 2 years ]
    FA findings, retinal sensitivity in Microperimetry, contrast sensitivity, Amsler Grid Test


Enrollment: 50
Study Start Date: April 2011
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Detailed Description:
Patients with central serous chorioretinopathy are recruited from the Department of Ophthalmology at the Medical University of Vienna. All patients undergo ETDRS visual acuity measurement, Pelli-Robson contrast examination, Amsler-Grid testing, questionnaire testing, ophthalmologic examination, SD-OCT and polarization-sensitive OCT, fundus autofluorescence, fluorescein angiography, indocyanine-green angiography, fundus photo and microperimetry. Patients are re-examined after an interval of 6 weeks until subretinal fluid is entirely reabsorbed to gain further insides in etiology, course and prognosis of this disease.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with an acute episode of central serous chorioretinopathy are recruited from the Department of Ophthalmology at the Medical University of Vienna.
Criteria

Inclusion Criteria:

  • Signed informed consent form
  • Age over 18 years
  • acute episode of Central Serous Chorioretinopathy
  • Symptoms for less than two weeks
  • no treatment on study eye

Exclusion Criteria:

  • bad compliance
  • protected patient group (pregnant women)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01378130


Locations
Austria
Vienna Gerenal Hospital
Vienna, Austria
Sponsors and Collaborators
Medical University of Vienna
Investigators
Principal Investigator: Stefan Sacu, Ass.Prof.Dr. Department of Ophthalmology, Medical University of Vienna, Austria
  More Information

Responsible Party: Stefan Sacu, Assoc. Prof. Dr., Medical University of Vienna
ClinicalTrials.gov Identifier: NCT01378130     History of Changes
Other Study ID Numbers: EK 180/2011
First Submitted: June 20, 2011
First Posted: June 22, 2011
Last Update Posted: April 26, 2013
Last Verified: April 2013

Keywords provided by Stefan Sacu, Medical University of Vienna:
CCS
CSC
Subretinal Fluid
multimodal imaging

Additional relevant MeSH terms:
Central Serous Chorioretinopathy
Retinal Diseases
Eye Diseases